Alzamend Neuro, Inc. ALZN 深 滬
等待開盤 02-07 09:30:00 美东时间
1.975
+0.105
+5.61%
華盛通- 最 高2.06
- 今 開1.87
- 成交量 4.32万股
- 最 低 1.87
- 昨 收 1.87
- 總市值 750.82万
- 52周最高 10.35
- 市盈率 靜 --
- 換手率 1.14%
- 52周最低 1.69
- 委 比 -15.25%
- 總股本 380.16万
- 歷史最高 45292.50
- 量 比 1.29
- 振 幅 10.16%
- 歷史最低 1.7804
- 每 手 1
- 風險率 2.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...
01-10 05:05
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $28
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $42 to $28.
2025-12-22 20:15
Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(1.96) by 84.65 percent. This is a 91.69 percent increase over losses of $(3.61) per share from
2025-12-10 06:37
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.
2025-11-19 20:30
Alzamend Neuro Issues New Common Stock Shares
Alzamend Neuro ( ($ALZN) ) has provided an announcement. Between October 1 and ...
2025-10-10 05:03
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
2025-09-26 09:45
Alzamend Neuro Boosts Liquidity with Stock Issuance
Alzamend Neuro ( ($ALZN) ) has provided an update. Between September 17 and Sep...
2025-09-26 05:01
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ: ALZN) with a Buy and lowers the price target from $45 to $42.
2025-09-25 20:02
Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.69) by 85.51 percent. This is a 88.79 percent increase over losses of $(11.42) per share from
2025-09-11 04:41
